10x Genomics Joins Forces with Fred Hutch to Enhance Cancer Research Through Innovative Technologies #United_States #oncology #Pleasanton #10x_Genomics #Fred_Hutch
@newsen.bsky.social
@newsen.bsky.social10x Genomics Joins Forces with Fred Hutch to Enhance Cancer Research Through Innovative Technologies #United_States #oncology #Pleasanton #10x_Genomics #Fred_Hutch
@bcc2026.bsky.social🎀 Breast Cancer Congress 2027
📅 June 17–18, 2027
📍 Zurich, Switzerland | 🌐 Online participation available
Hosted by Sciinov Group
#BreastCancer #Oncology #CancerResearch #BreastCancer2027 #MedicalConference
@christieinstitute.bsky.socialExplore the Cancer Rehabilitation Study Day programme, covering the patient journey from prehabilitation to palliative care.
22 October 2026 | Hybrid
View the agenda and book your place
🔗 bit.ly/canrehabblue...
@ashlesham89.bsky.socialThe global Melanoma Therapeutics Market is projected to grow from USD 11.25 billion in 2026 to USD 25.55 billion by 2034, at a 10.8% CAGR.
Get Free Sample:
straitsresearch.com/report/melan...
#Melanoma #CancerTherapeutics #Immunotherapy #Oncology #Healthcare #MarketResearch
@diseaseatlas.bsky.socialKnowing a gene drives a disease is not knowing how. Disease Atlas by Euretos traces the cascade: ERBB2 (HER2) in breast cancer, from EGF-ERBB2-RAS-ERK into PI3K-AKT-mTOR, to epithelial cell proliferation in the mammary epithelial cell. Mechanism, not correlation. #Oncology
@currentmedscience.bsky.socialElevated NCAPD3 expression drives #HCC #metastasis. Inhibition impedes tumor growth and metastatic potential by blocking PI3K–AKT signaling, underscoring translational promise in #Oncology #medsky
Full article: doi.org/10.1007/s115...
@norml.org🌿 Patients reported improvements in appetite, sleep, pain, nausea, anxiety, and depression.
That relief can make it possible to share a meal, rest, and be present with the people they love.
🔗 Read more: norml.org/news/2026/09...
@onclive.bsky.social🫁 Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in the FURVENT trial. #lcsm #oncology
Full story ➡️: www.onclive.com/view/firmone...
@onclive.bsky.socialThe addition of the anti-CD105 antibody carotuximab to apalutamide improved PFS vs apalutamide alone in mCRPC #pcsm #oncology
Check out the data and how they are shaping the ongoing phase 2 study: www.onclive.com/view/carotux...
@onclive.bsky.socialA @mayocliniccancer.bsky.social study found that fractionated stereotactic radiosurgery reduced the risk of cancer returning after surgery for brain metastases and was associated with improved survival vs radiation given in a single treatment #oncology www.onclive.com/view/study-f...
@onclive.bsky.socialWATCH 🎥: Alexis Ann LeVee, MD, previews the lidERA Breast Cancer PRO data being presented at the 2026 ESMO Congress. @myesmo.bsky.social #ESMO2026 #bcsm #oncology
Sign up to read the full preview ➡️: www.onclive.com/view/breast-...
@onclive.bsky.socialWATCH 🎥: @kalinskykevin.bsky.social, of @winshipcancer.emory.edu, discusses key breast cancer abstracts being presented at the 2026 ESMO Congress. @myesmo.bsky.social #ESMO2026 #bcsm #oncology
Sign up to read our preview article for more insights ➡️: www.onclive.com/view/breast-...
@onclive.bsky.socialRuxolitinib cream reduced affected lesional BSA more than placebo vehicle at day 28 in patients with epidermal or superficially sclerotic cutaneous cGVHD #oncology
Dive into the phase 2 data: www.onclive.com/view/ruxolit...
@onclive.bsky.socialA real-world study from @moffittnews.bsky.social showed talquetamab produced similar response rates in patients with relapsed/refractory multiple myeloma, irrespective of whether they met the eligibility criteria for MonumenTAL-1 #mmsm #oncology
Read more: www.onclive.com/view/talquet...
@onclive.bsky.social🫁 Lung cancer experts discuss strategies after immunotherapy in advanced squamous NSCLC. @narjustflorezmd.bsky.social @christianrolfo.bsky.social @cityofhope.bsky.social @osucccjames.bsky.social @danafarber.bsky.social @iaslc.bsky.social #WCLC26 #lcsm #oncology
@marketresearcher.bsky.socialThe global leukemia therapeutics market is projected to reach $36.44 billion by 2034, growing at a 6.9% CAGR from 2026 to 2034.
Request a Free Sample: straitsresearch.com/report/leuke...
#LeukemiaTherapeutics #CancerTreatment #Oncology #Pharmaceuticals #Healthcare #MedicalResearch #MarketResearch
@carlus-2024.bsky.socialOctober 6, 2026
👉 A Quebec discovery moving closer to patients.
🙂 Another encouraging news story from Groupe UIG.
Read: stemcellnetwork.ca/news/stem-ce...
#Biotech #LifeSciences #Innovation #Quebec #Montreal #StemCells #RegenerativeMedicine #Oncology #Research #Commercialization
@ashlesham89.bsky.socialThe global Immunoprotein Diagnostic Testing Market was valued at USD 10.39 Billion in 2025 and is projected to reach USD 18.38 Billion by 2034, growing at a CAGR of 6.54% during 2026–2034.
Get Free Sample:
straitsresearch.com/report/immun...
@thecancersurvivorsclub.comFDA oncology approvals between July and September expanded options for pancreatic, breast, lung, skin, kidney, bile duct and blood cancers, as well as some solid tumours with specific genetic alterations.
@onclive.bsky.social📰 Just in: Epcoritamab plus R-CHOP improved PFS vs R-CHOP alone in newly diagnosed DLBCL, meeting the primary end point of the phase 3 EPCORE DLBCL-2 trial #lymsm #oncology
Dive into the topline findings: www.onclive.com/view/epcorit...
